Activator of: -Mercaptoethanol, 2-crystallin, 3-crystallin, E-crystallin, N-crystallin, -crystallin, 20S Proteasome 5, 3010026O09Rik, 3110003A17Rik, 4933437F05Rik, Aasdh, ACAT-3, ADAM25, AKR1A1, AKR1CL1, AKR7A3, ALDH3A2, ALG8, ALR, APNG, Arylsulfatase B, Asparagine synthetase, Blue Carrier Protein-sterile, BLVRB, C2orf34, C9orf21, COASY, COMMD7, COX19, CPXM2, CSAD, CTU1, CYB561D1, CYB561D2, CYBASC3, CYBRD1, CYHR1, CysRS, Cystinosin, Cytoplasmic CysRS, DFNB59, DHRS12, DHRS7, Dim1, DIO1, DPEP3, EAAT1, EG436008, ERIS, ERp19, ESD, ETHE1, FAM213A, Fatso, Fdx1, Gamma-glutamyltransferase (GGT), GCAT, GCL, GGL, GGT6, Glyoxalase II, Gm97, GPx-3, GPx-6, Grx1, Grx2, GRXCR1, GSTT3, H2-Dd, HEI-C, Hepatocyte Specific Antigen, hMLH3, HS3ST1, HYPB, ISCA1, IscU1, IscU2, Kell, KSP37, L2HGDH, LMBRD1, LOC150383_2210021J22Rik, MAT II, Meprin A, MGST2, MICAL1, MICAL2, Mitochondrial CysRs, MMAA, MMADHC, MsrA, MsrB2, murinoglobulin 2, NAF1, NAT-8L, NDOR1, NIPA1, NNT, Nucleoredoxin, NUDT11, NUDT18, NXNL2, ODF3B, OPLAH, OR51AA4, PAM, PANK4, PAPSS 2, PDILT, PET112L, PGD synthase, pHyde, PIWIL4, Plasmodium Aldolase, PQLC1, Prdx6b, PRODH, PROSC, PRX III, PRX2, PYROXD2, QSER1, quiescin Q6, RDH7, Rhodanese, ROPN1, Rubisco activase, S-100, SCARA3, SDR39U1, SELENBP1, Seleniumm Solution, selenocysteine lyase, Selenoprotein M marker, Selenoprotein N, Selenoprotein P, Selenoprotein R, Selenoprotein T, SLA/LP, SPLUNC3, SPTRX-3, SSSCA1, Sulfiredoxin, SVCT2, TGase2, TPRX1, Transcobalamin II, TRFP, TrxR1, TSPAN1, TUSC3, TXNDC14, TXNDC15, TXNDC16, TXNDC4, TXNDC9, TXNL1, TXNL6, Tyrosinase, UQCRHL, Urm1, UROD, UTP23, vanin-3, VAT1L, VKOR, VKORC1L1, and ZnT-1.
Given these reported outcomes regarding weight reduction and appetite control in obesity associated with the MC4R pathway, it is plausible to hypothesize that setmelanotide may exert similar effects in MC4R-deficient obesity
Pricing Structure (per company website): First month : $149.97 Subsequent months : $249.97 per month Multi-month options : 3 months ($449.97), 6 months ($809.95), 12 months ($1,349.97) The platform states that pricing remains consistent regardless of dosage adjustments
3A,C,E)
